• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Medications for PTSD

Medications for PTSD

November 1, 2011
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Elizabeth Tien, MD

Trauma-focused psychotherapies are the gold standard for treating PTSD in children and adolescents,
as recommended in the 2010 AACAP practice parameters. Many studies support the use of psychotherapy in contrast to the lack of research for medications. First line treatment of PTSD should always consist of psychotherapy but medications are often used in the hopes of further improving symptoms.

Table 1 - Medications for Pediatric PTSD - Provides a summary of drug options.

SSRIs

Two medications are FDA approved for the treatment of PTSD in the adult population, the SSRIs sertraline (Zoloft) and paroxetine (Paxil). No medications are FDA approved for treating children with PTSD. Out of the handful of randomized controlled trials looking at medication use in children and adolescents for PTSD, two include the use of sertraline (Cohen JA et al,J Am Acad Child Adolesc Psychiatry 2007;46(7):811–19 and Robb A et al, J Child Adolesc Psychopharmacol 2010;20(6);463–71).

While they both demonstrated some improvements, they were not significant. The Cohen study was limited to 24 girls with sexual abuse trauma, and the only difference found was in the Child Global Assessment Scale for the sertraline plus therapy group. The Robb study was larger, with 131 patients, but showed no significant benefit with sertraline. In fact, there was a higher dropout rate in the medication group.

In another RCT study, no differences were found between fluoxetine (Prozac), imipramine (Tofranil), and placebo for acute stress symptoms, but this study was extremely short (seven days) and several patients received other anxiolytic meds such as benzodiazepines and beta-blockers (Robert R et al, Burns 2008;34(7):919–28). While it may be helpful to use SSRIs for some children, the benefits are not well established and it is important to monitor for tolerability, particularly in the post black box world. The dosing in this case would be the same as for depression.

Non-SSRI Antidepressants

If you are starting to feel uncomfortable about the lack of evidence-based data, get ready for more uncharted territory. While adult studies have shown some efficacy of non-SSRI antidepressants including MAOIs, SNRIs, TCAs, trazodone (Oleptro), nefazodone (Serzone), and mirtazapine (Remeron), there is very little evidence to generalize this to children. One RCT found imipraminesymptoms in pediatric burn patients; however this was another short study with no placebo comparison, and no follow up beyond seven days (Robert R et al, J Am Acad Child Adolesc Psychiatry 1999;38(7):873–82).

Antipsychotics
The use of atypical antipsychotics has increased exponentially in children, and there is evidence that suggests an increase in dopamine in children with PTSD (De Bellis MD et al, Biol Psychiatry 1999;45(10):1271–84). Some improvements were noted through a report on three children treated with risperidone (Risperdal), a case series of six boys with quetiapine (Seroquel), and even treatment with clozapine (Clozaril), but further evidence is needed. The clozapine study was retrospective, limited to a residential population, and only had 19 patients with a PTSD diagnosis (Kant R et al, J Child Adolesc Psychopharmacol 2004;14(1):57–63). The sedating effects and dopamine blocking may be helpful with fear response and intrusive symptoms of PTSD but the potential benefits must be weighed carefully with the metabolic and extrapyramidal side effects. Typically, you would give these medications at a lower dose compared to treating psychotic disorders.

Antiadrenergics

The use of alpha and beta-adrenergic agents, such as clonidine (Catapres), guanfacine (Tenex), and propranolol (Inderal), has also demonstrated some response in children through a smattering of case studies and one randomized control study of propranolol in 29 children. These medications may help address hyperarousal symptoms in children and the noradrenergic dysregulation that is found with PTSD. Clonidine would start at 0.05 mg at bedtime with an increase in dose frequency of two or three times a day due to the short half life. Recent research has looked at the alpha-antagonist prazosin (Minipress) through case studies in children. Prazosin would be given 1 mg per day at bedtime up to a dose of 4 mg per day and can be particularly helpful with sleep.

Mood Stabilizers

When considering complex PTSDand the emotional dysregulation that is often present, the use of mood stabilizers seems reasonable. Studies in children include an RCT for divalproex sodium (Depakote) which showed symptom improvement at higher blood levels (Steiner H et al, Child Psychiatry Hum Dev 2007;38(3):183–93), and an open label study for carbamazepine (Tegretol) which also showed some improvements (Looff D et al, J Am Acad Child Adolesc Psychiatry 1995;34(6):703–4). The divalproex study used data from a previous trial and was limited to 12 incarcerated, conduct disorder boys, while the Looff study included 28 children, of whom several also received other psychotropic medications. Adult studies have shown some efficacy with lamotrigine (Lamictal), tiagabine (Gabitril), and topiramate (Topamax). Overall, the results have not been as promising as expected, and further research is needed.

Benzodiazepines

As PTSD falls under the DSM category of anxiety disorders, the use of benzodiazepines may be considered. However, there are essentially no studies that look at the efficacy of benzodiazepines in children for PTSD. This may be due to several reasons, including the increased risk of disinhibition in children, the limited amount of research in treating children with benzodiazepines for any indication, and the lack of evidence supporting its use in adult patients with PTSD. Another consideration is the significant rate of comorbid substance abuse with PTSD.

Opiates

While on the topic of potential substances of abuse, a naturalistic study looked at the use of morphine and the development of PTSD in hospitalized children with acute burns and found a reduction in PTSD symptoms with higher doses of morphine (Saxe G et al, J Am Acad Child Adolesc Psychiatry 2001;40(10):915–21). This may be due to an association with fear conditioning and memory consolidation. While this study followed the 24 children six months out, it would be difficult to sell the use of morphine in children without physical pain.

Other Possible Agents

Other medications that have been considered include cyproheptadine (Periactin), an antihistamine and 5-HT2 antagonist, with several case reports in adults and one case report in children. Improvements were found in intrusive symptoms, specifically nightmares. Dysregulation of the HPA axis suggests possible use of medications that act on corticotrophin-releasing.
Child Psychiatry
KEYWORDS anxiety_disorder child-psychiatry ptsd
    www.thecarlatreport.com
    Issue Date: November 1, 2011
    SUBSCRIBE NOW
    Table Of Contents
    Psychotherapy for Pediatric PTSD
    Medications for PTSD
    EMDR in Children and Adolescents
    The Neurobiology of Trauma
    Trauma-Focused Cognitive Behavioral Therapy
    Does Co-Sleeping Cause Behavior Problems?
    Risperdal not Effective for Anorexia Nervosa
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2639254965.jpg
      General Psychiatry

      Psychopharm Secrets: Starting Meds

      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.